High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation

Blood

Volumn 125, Issue 1, 2015, Pages 199-205

  Ponce, Doris M ^a,b   Hilden, Patrick ^a   Mumaw, Christen ^c   Devlin, Sean M ^a   Lubin, Marissa ^a   Giralt, Sergio ^a,b   Goldberg, Jenna D ^a,b   Hanash, Alan ^a,b   Hsu, Katharine ^a,b   Jenq, Robert ^a,b   Perales, Miguel Angel ^a,b   Sauter, Craig ^a,b   Van Den Brink, Marcel R M ^a,b   Young, James W ^a,b   Brentjens, Renier ^a,b   Kernan, Nancy A ^a   Prockop, Susan E ^a   O'Reilly, Richard J ^a,b   Scaradavou, Andromachi ^a   Paczesny, Sophie ^c   Barker, Juliet N ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CYCLOSPORIN A; ELAFIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN; REGENERATING ISLET DERIVED PROTEIN 3 A; SCATTER FACTOR; SUPPRESSOR OF TUMORIGENICITY 2 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; HLA ANTIGEN; IL1RL1 PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHILD; COHORT ANALYSIS; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; REDUCED INTENSITY CONDITIONING; SEROLOGY; SURGICAL MORTALITY; TRANSPLANT RELATED MORTALITY; ADVERSE EFFECTS; BLOOD; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; INFANT; METABOLISM; MIDDLE AGED; MORTALITY; NEUTROPHIL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TIME FACTOR; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; INFANT; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPHILS; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84920590621     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-584789     Document Type: Article

References (48)

1. Barker JN, Byam CE, Kernan NA, et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant. 2010; 16(11): 1541-1548.
2. Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013; 121(5): 752-758.
3. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007; 110(8): 3064-3070.
4. MacMillan ML, Weisdorf DJ, Brunstein CG, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 2009; 113(11): 2410-2415.
5. Ponce DM, Gonzales A, Lubin M, et al. Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant. 2013; 19(6): 904-911.
6. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010; 116(22): 4693-4699.
7. Ponce DM, Zheng J, Gonzales AM, et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(9): 1316-1326.
8. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009; 113(2): 273-278.
9. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010; 2(13): ra2.
10. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011; 118(25): 6702-6708.
11. Harris AC, Ferrara JL, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012; 119(12): 2960-2963.
12. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012; 119(16): 3854-3860.
13. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013; 369(6): 529-539.
14. Alsultan A, Giller RH, Gao D, et al. GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplant. 2011; 46(5): 668-675.
15. Snover DC Mucosal damage simulating acute graft-versus-host reaction in cytomegalovirus colitis. Transplantation. 1985; 39(6): 669-670.
16. Bombí JA, Nadal A, Carreras E, et al. Assessment of histopathologic changes in the colonic biopsy in acute graft-versus-host disease. Am J Clin Pathol. 1995; 103(6): 690-695.
17. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation. Gastrointest Endosc. 1999; 49(5): 612-621.
18. Liakopoulou E, Mutton K, Carrington D, et al. Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation. Bone Marrow Transplant. 2005; 36(8): 691-694.
19. Selbst MK, Ahrens WA, Robert ME, Friedman A, Proctor DD, Jain D. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol. 2009; 22(6): 737-743.
20. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012; 54(8): 1053-1063.
21. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011; 117(8): 2332-2339.
22. Barker JN, Abboud M, Rice RD, et al. A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions. Biol Blood Marrow Transplant. 2009; 15(12): 1596-1602.
23. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997; 97(4): 855-864.
24. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12): 945-956.
25. Copelan E, Casper JT, Carter SL, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007; 13(12): 1469-1476.
26. Saha P, Heagerty PJ. Time-dependent predictive accuracy in the presence of competing risks. Biometrics. 2010; 66(4): 999-1011.
27. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005; 92(4): 965-970.
28. Eapen M, Klein JP, Sanz GF, et al.; Eurocord-European Group for Blood and Marrow Transplantation; Netcord; Center for International Blood and Marrow Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011; 12(13): 1214-1221.
29. Dahi PB, Ponce DM, Devlin S, et al. Donor-recipient allele-level HLA matching of unrelated cord blood units reveals high degrees of mismatch and alters graft selection. Bone Marrow Transplant. 2014; 49(9): 1184-1186.
30. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011; 117(25): 6963-6970.
31. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006; 108(8): 2874-2880.
32. Chen YB, Aldridge J, Kim HT, et al. Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012; 18(5): 805-812.
33. Sanz J, Arango M, Senent L, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant. 2014; 49(3): 397-402.
34. Lindemans CA, Chiesa R, Amrolia PJ, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood. 2014; 123(1): 126-132.
35. Dinarello CA Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117(14): 3720-3732.
36. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5): 479-490.
37. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013; 39(6): 1003-1018.
38. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010; 115(9): 1843-1849.
39. Eapen M, Klein JP, Ruggeri A, et al.; Center for International Blood and Marrow Transplant Research, Netcord, Eurocord, and the European Group for Blood and Marrow Transplantation. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014; 123(1): 133-140.
40. Malard F, Szydlo RM, Brissot E, et al. Impact of cyclosporine - A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16(1): 28-34.
41. Mori T, Kato J, Shimizu T, et al. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Biol Blood Marrow Transplant. 2012; 18(2): 229-234.
42. Ram R, Storer B, Mielcarek M, et al. Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18(3): 414-422.
43. Rogosheske JR, Fargen AD, DeFor TE, et al. Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival. Bone Marrow Transplant. 2014; 49(1): 122-125.
44. Jacobson PA, Huang J, Wu J, et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2010; 16(3): 421-429.
45. Harnicar S, Ponce DM, Mathew S, et al. Higher mycophenolic acid (MPA) trough levels result in lower day 100 severe acute graft-versus-disease disease (aGVHD) without increased toxicity in double-unit cord blood transplantation (CBT) recipients. Biol Blood Marrow Transplant. 2014; 20(2):S52-S53.
46. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012; 209(5): 903-911.
47. Hanash AM, Dudakov JA, Hua G, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012; 37(2): 339-350.
48. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996; 88(8): 3230-3239.